Redefining R&D

How Immunoscience is Driving the Pipeline of the Future

Our Latest Stories

Social Impact

September 25, 2024

Foundation S at UNGA: Addressing Climate and Health Resilience

/assets/dotcom/content-app/events/banner-investors-events_20230703194346.jpg

Third quarter 2024 results

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. 

Friday October 25, 2024
14:00 - 15:30 CET (8:00am – 9:30am EST)

United by Purpose

Each of us plays a unique role in bringing our purpose to life.

Igniting the Potential in Everyone

We’re proud to be premium partner of Paris 2024.

Science and sport aren’t that different. Just like athletes do, we overcome setbacks to keep moving forward, not just for ourselves, but for our patients, colleagues, families and friends.

About Us

Who We Are

We are an innovative global healthcare company.

Our Pipeline

5

Therapeutic areas

78

Compounds in clinical development

29

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases

September 26, 2024
Press Release: Availability of the Q3 2024 Aide mémoire
September 25, 2024
Media Update: EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases
September 20, 2024
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
September 20, 2024
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old